How can fatty liver disease be prevented and treated?

Fatty liver disease—also known as hepatic steatosis—is a common, reversible condition characterized by excessive accumulation of fat in hepatocytes (liver cells). It is broadly categorized into two main types: alcoholic fatty liver disease (AFLD), linked to heavy or prolonged alcohol use, and nonalcoholic fatty liver disease (NAFLD), which occurs in individuals with little or no alcohol consumption and is strongly associated with metabolic syndrome—including obesity, insulin resistance, type 2 diabetes, dyslipidemia, and hypertension.

Prevention and management hinge on lifestyle modification as the cornerstone of therapy. Weight loss—achieved through caloric restriction and increased physical activity—is the most evidence-based intervention. A sustained weight reduction of 5–10% has been shown to significantly decrease hepatic fat content, improve liver enzyme levels (e.g., ALT, AST), and reduce inflammation and fibrosis in patients with NAFLD. Aerobic exercise (e.g., brisk walking, cycling, swimming) for at least 150 minutes per week, combined with resistance training twice weekly, confers additive benefits independent of weight loss.

Nutrition plays a pivotal role. A Mediterranean-style diet—rich in monounsaturated fats (e.g., olive oil, nuts), omega-3 fatty acids (e.g., fatty fish), fiber (e.g., whole grains, legumes, vegetables), and antioxidants—is strongly supported by clinical evidence. Conversely, intake of refined carbohydrates (especially fructose-sweetened beverages), saturated and trans fats, and ultra-processed foods should be minimized. Alcohol abstinence is mandatory for AFLD and strongly recommended—even in modest amounts—for individuals with NAFLD, given its potential to exacerbate liver injury.

Pharmacologic therapy remains adjunctive and individualized. While no drug is currently FDA-approved specifically for NAFLD/NASH (nonalcoholic steatohepatitis), pioglitazone (a thiazolidinedione) and vitamin E (alpha-tocopherol) are considered in select non-diabetic adults with biopsy-proven NASH. GLP-1 receptor agonists (e.g., semaglutide) show promising results in reducing liver fat and fibrosis in ongoing trials and may be used off-label when aligned with broader metabolic goals. Statins are safe and appropriate for managing concomitant dyslipidemia and do not worsen liver injury.

Regular monitoring is essential. Patients should undergo baseline assessment including liver biochemistry, ultrasound, and risk stratification for advanced fibrosis (e.g., using noninvasive tools like FIB-4 or ELF test). Those with high-risk features—such as persistently elevated ALT/AST, type 2 diabetes, or obesity—may benefit from referral to hepatology for further evaluation, including transient elastography (FibroScan®) or, in select cases, liver biopsy.

Early recognition and consistent, multidisciplinary intervention—including collaboration among primary care providers, endocrinologists, dietitians, and hepatologists—can halt progression, reverse early-stage disease, and prevent complications such as cirrhosis, hepatocellular carcinoma, and liver-related mortality.